Glycosylation is one of the most common post-translational protein modifications. Carbohydrate-mediated interactions between cells and their environment are important in differentiation, embryogenesis, inflammation, cancer and metastasis and other processes. Humans and mice with mutations
that prevent normal N-glycosylation show multi-systemic defects in embryogenesis, thereby proving that these molecules are essential for normal development; however, a large number of proteins undergo defective glycosylation in these human and mouse mutants, and it is therefore difficult to determine the precise molecular roles of specific N-glycans on individual proteins. We describe here a 'functional post-translational proteomics' approach that is designed to determine the role of N-glycans on individual glycoproteins in the development of Caenorhabditis elegans.
Developmental glycobiology: protein-bound glycans are essential for normal metazoan development
The importance of protein-bound glycans in the development of metazoan animals is now widely recognized. Mutations in the genes encoding lysosomal glycosidases [1, 2] and UDP-N-acetylglucosamine (GlcNAc): lysosomal-enzyme GlcNAc-1-phosphotransferase (which is required for targeting of many glycosidases to the lysosomes) [3] [4] [5] have long been known to cause various congenital lysosomal storage diseases. Other examples of congenital diseases with defective protein glycosylation are the progeroid form of Ehlers-Danlos syndrome [6, 7] , leucocyte adhesion deficiency type II [8] and the congenital disorders of glycosylation [9] [10] [11] [12] . Six type I and four type II congenital disorders of glycosylation have been described to date.
Phenotypes have been determined for mice with targeted or natural mutations in the genes that encode UDP-GlcNAc:␣3-Dmannoside ␤1,2-N-acetylglucosaminyltransferase I (GlcNAcT I) [13, 14] , UDP-GlcNAc:␣6-D-mannoside ␤1,2-N-acetylglucosaminyltransferase II (GlcNAcT II) [15, 16] , UDP-GlcNAc:␤4-D-mannoside ␤1,4-N-acetylglucosaminyltransferase III [17] [18] [19] , UDP-GlcNAc:␣6-D-mannoside ␤1,6-N-acetylglucosaminyltransferase V (GlcNAcT V) [20, 21] , UDP-Gal:GlcNAc ␤1,4-galactosyltransferase I [22] [23] [24] , ␣3,6-mannosidase II [25, 26] , ␣1,3-fucosyltransferase VII [27] [28] [29] , O-GlcNAc-transferase [30] , the protein encoded by the Large gene [31] and other glycosyltransferases [32] [33] [34] [35] [36] [37] [38] [39] .
In humans and mice, the phenotypes of these various mutations range from embryonic lethality, to severe multi-systemic developmental abnormalities, to relatively mild defects in the immune and other systems. The GlcNAcT I null mutation has relatively little effect on viability or growth in Chinese hamster ovary (CHO) and baby hamster kidney cells [40] [41] [42] [43] , but is lethal to the mouse embryo [13, 14] , which indicates that hybrid and complex N-glycans are essential for cell-cell interactions and development in multi-cellular animals.
Defective protein glycosylation has also been shown to result in abnormal development in Drosophila melanogaster [44, 45] and Caenorhabditis elegans. The sqv (squashed vulva) genes are a set of eight independent loci in C. elegans, which are required for the invagination of vulval epithelial cells, normal oocyte formation and embryogenesis [46, 47] . The sqv-3, sqv-7 and sqv-8 genes all affect the biosynthesis of glycosaminoglycans [48] . The sqv-7 gene encodes a multi-transmembrane hydrophobic protein that can transport several nucleotide sugars [UDP-glucuronic acid, UDP-N-acetylgalactosamine, UDP-galactose (UDP-Gal)] into the Golgi lumen for the biosynthesis of glycoconjugates that are required for development [49] . The sqv-3 gene is homologous with the human gene that encodes UDP-Gal:xylose-␤1-O-Ser-R ␤1,4 galactosyltransferase I, which is involved in the synthesis of the glycosaminoglycan-protein linkage region of proteoglycans [50] ; a defect in this enzyme has been shown to be the cause of the progeroid form of Ehlers-Danlos syndrome [6, 7] . The C. elegans genome contains at least 100 genes that are homologous with genes that are mutated in human disease [51] , which suggests that other human disease genes causing abnormal glycosylation may have C. elegans homologues.
It is clear therefore that interference with normal glycosylation disrupts development in humans, mouse and invertebrates, indicating that proteinbound glycans play essential roles in metazoan development.
Function of specific glycans on specific glycoproteins
In order to understand exactly what a protein-bound glycan is doing at the molecular level, it is essential to understand its precise role in the function of a specific protein. There are several excellent examples that provide this type of information in the literature.
The congenital lysosomal storage disease mucolipidosis II (inclusion cell disease or I-cell disease) and a milder form named mucolipidosis III (Pseudo-Hurler polydystrophy) provide such an example [1] . These diseases are caused by multiple deficiencies in lysosomal enzymes, which result due to defective targeting of these enzymes to the lysosome [5] . The defective gene encodes UDP-GlcNAc:lysosomal-enzyme GlcNAc-1-phosphotransferase which transfers GlcNAc␣1-O-phosphate to C-6 of the mannose residues of certain oligomannose N-glycans on lysosomal hydrolases. The GlcNAc is subsequently removed by GlcNAc-1-phosphodiester ␣-N-acetylglucosaminidase [3, 52] to expose the mannose 6-phosphate signal required for recognition by the mannose 6-phosphate receptors and subsequent lysosome targeting. The phospho-GlcNAc-transferase has been cloned [4, 53, 54] and the defects responsible for improper targeting in mucolipidosis III have been determined [4] .
The E-, P-and L-selectins are proteins with lectin domains that bind to carbohydrate moieties on their respective glycoprotein ligands. The interactions between the selectins and their ligands play important roles in various aspects of the immune system such as lymphocyte homing and the extravasation of lymphocytes from the capillary lumen into the tissues at sites of inflammation. Although details remain to be resolved, the mechanisms by which the selectins function are now reasonably well understood [28, [55] [56] [57] [58] .
Two recent examples of great interest to developmental glycobiologists involve oligosaccharides that are linked to protein by Fuc␣1-O-Ser/Thr or Man␣1-O-Ser/Thr. Notch is a large cell-surface receptor, which is known to be an essential player in a wide variety of developmental cascades. Fringe proteins can positively and negatively modulate the ability of Notch ligands to activate the Notch receptor. The Drosophila and mammalian genes that encode Fringe proteins have been cloned and the proteins have been shown to be UDP-GlcNAc:Fuc␣1-O-Ser/Thr-R ␤1,3-N-acetylglucosaminyltransferases that initiate elongation of O-linked fucose residues attached to epidermal growth factor-like sequence repeats of Notch [59, 60] . Fringe enzymic activity is essential for its modulatory action. The enzyme that adds O-fucose to epidermal growth factor-like repeats, GDP-Fuc:protein O-fucosyltransferase, has also been cloned [61] . The O-linked oligosaccharide in CHO cells has the structure Sialyl␣2,3Gal␤1,4GlcNAc␤1,3Fuc␣1-O-Ser/Thr [62] . The trisaccharide Gal␤1,4GlcNAc␤1,3Fuc␣1-O-Ser/Thr is the minimal O-fucosylated glycan which can support Fringe modulation of Notch signalling [63] .
Dystroglycan (dystrophin-associated glycoprotein) is a cytoskeletonlinked extracellular matrix receptor that is expressed in many cell types and is composed of ␣-and ␤-subunits that are encoded by a single mRNA [64] . Dystroglycan is a central component of the dystrophin-glycoprotein complex, a protein assembly that plays a critical role in a variety of muscular dystrophies [65] . The major sialylated O-glycosidically linked oligosaccharide of bovine peripheral nerve [66] and rabbit skeletal muscle [67] ␣-dystroglycan is a novel O-mannosyl-type oligosaccharide, Sialyl␣2,3Gal␤1,4GlcNAc␤1,2Man␣1-OSer/Thr [68] . This oligosaccharide is probably required for the binding of laminin to ␣-dystroglycan. A human enzyme homologous with GlcNAcT I, UDP-GlcNAc:␣-D-mannoside ␤-1,2-N-acetylglucosaminyltransferase I.2 (GlcNAcT I.2) [69] [70] [71] [72] [73] , appears to be responsible for the synthesis of the GlcNAc␤1,2Man␣1-O-Ser/Thr moiety of ␣-dystroglycan since six patients with muscle-eye-brain disease [MIM 253280 (Mendelian Inheritance in Man database; www.ncbi.nlm.nih.gov)] have been shown recently to have mutations in the GlcNAcT I.2 gene [73] . Muscle-eye-brain disease is an autosomal recessive disease of previously unknown aetiology, which is characterized by severe mental retardation, ocular abnormalities, congenital muscular dystrophy and a polymicrogyria-pachygyria-type neuronal migration disorder of the brain.
Challenges of post-translational modifications
The above examples of glycan function are, of course, most interesting and exciting; however, in 1999, Apweiler et al. [74] estimated that 65-69% of the proteins in all of the metazoan databases contain at least one potential Nglycosylation consensus sequence (sequon Asn-Xaa-Ser/Thr where Xaa can be any amino acid except proline) and thus may be N-glycosylated. The number of proteins filed as N-glycoproteins at the time was 7942, but the authors concluded that at least half of all metazoan proteins probably contain N-glycans. The number of proteins with other types of glycans is no doubt equally large. To make matters even more complicated, there are hundreds of other types of post-translational modifications [75, 76] . Will it ever be possible to determine the functions of the thousands of proteins that are present in every metazoan genome by the various 'functional proteomics' approaches now being widely used and promoted (e.g. comparison of different tissues or biological states by micro-array technology; determination of protein binding patterns)? Even more problematic, will it ever be possible to determine the role that a specific post-translational modification plays in the function of a specific protein for every protein in the genome? Even if one assumes that the lessons learned for a particular modification on a particular protein can probably be extrapolated to groups of other similar proteins, the task seems impossibly difficult.
The function of a gene and the protein it encodes can be studied in various ways. The most direct method is to study the function of a natural or recombinant form of the protein using in vitro assays. The role of post-translational modifications can then be determined. Alternatively, one can use cells in culture in a variety of approaches to study gene and protein function, e.g. Stanley and colleagues [77] [78] [79] have made major contributions to our understanding of glycan function by developing a series of lectin-resistant mutant CHO cell lines. There are some limitations to the use of such somatic cell mutants. Cell lines deficient in GlcNAcT I, for example, cannot make hybrid or complex N-glycans, but nevertheless have an essentially normal phenotype [40] [41] [42] [43] . Similar results have been obtained with somatic cell mutants that are unable to make various types of proteoglycans [80] and O-glycans [81] . One must therefore use animal models if one wishes to determine the functions of glycans that are not essential for cell viability and growth, or to study the role of glycans in development and morphogenesis.
Mutations in genes that affect glycosylation have been studied in humans, mice and invertebrates (see above) and have provided a large body of information on glycan function. An excellent review by Stanley [82] outlined the many new insights obtained by the study of transgenic mice that mis-express or overexpress a particular glycosyltransferase and of mice with targeted mutations in a glycosyltransferase gene. The author concluded that "it is now apparent that every glycosylation-defective mouse has been enormously informative"; however, the author also pointed out that "identifying the molecular basis of an altered glycosylation phenotype is difficult because glycosyltransferases modify many substrates and because related glycans are expressed on different glycoconjugates". A transgenic or 'knockout' mouse model can certainly be used to identify some of the protein targets which are acted on by the glycosyltransferase being studied. The role of the glycan in the function of such a protein can then be studied by in vitro assays using proteins in which glycosylation has been altered (e.g. by treatment with glycosidases, protein expression in the presence of glycosylation inhibitors, or expression of proteins with mutations that alter glycosylation).
Proteomics
The proteome defines the protein complement of a cell or tissue in a given state at a given time. Proteomics is the science of determining the nature of the proteome and it can be divided into structural and functional proteomics. There is a tendency to equate proteomics with rapid, high-throughput technology and indeed, such approaches are highly desirable, if possible. Functional proteomics usually means quantitative comparisons of different cells or tissues in different states and/or at different times by various high-throughput, highresolution separation methods, DNA and protein micro-arrays, and protein-binding assays.
Post-translational modifications create major complications for the field of proteomics (see above). There have been several recent reports on the application of the proteomics approach to this problem. Protein glycosylation and phosphorylation have been studied by selective identification of post-translational modifications with modification-specific fragment ions produced by collision-induced dissociation during analysis of peptides by liquid chromatography-electrospray-MS [83, 84] . The nano-electrospray ion source (NanoES) has been used for similar studies [85] . The phosphate moieties of phosphoserine/threonine-containing peptides can be replaced chemically by affinity tags and the tags can be used to enrich the phosphopeptides prior to MS analysis [86, 87] . A method has been developed that utilizes phosphoprotein isotopecoded affinity tags, which combines stable isotopes and biotin-labelling to enrich and quantitatively measure differences in the O-phosphorylation states of proteins [88] . Aebersold's group [89] has described a rapid and general method for the analysis of protein phosphorylation in complex protein mix- [90] and MS [91] [92] [93] [94] for many years. These reports indicate that structural post-translational proteomics is a promising area for future studies. The next hurdle is functional post-translational proteomics. We consider this term to mean a general approach to determining the function of a specific post-translational modification on a specific protein. This definition implies a protein-by-protein approach and therefore rules out high-throughput technology. In the remainder of this chapter, we outline a procedure for carrying out functional post-translational proteomics using N-glycans as the post-translational modification under study and C. elegans as the model organism. 
Is C. elegans suitable for the study of N-glycosylation?
C. elegans is considered to be the most completely understood metazoan in terms of anatomy, genetics, development and behaviour [95] [96] [97] . The organism is a free-living soil nematode worm, approx. 1 mm in length, with a life cycle of approx. 3 days. The locations, characteristics and lineages of all the somatic cells in the organism and a complete 'wiring diagram' of cell contacts have been determined and the complete genomic DNA sequence is available. The study of mutant alleles of developmentally important genes has provided detailed information on the developmental biology of the worm. The haploid genome contains 10 8 nucleotide pairs with approx. 18 000 genes. Worm mutants are readily obtained by chemical or irradiation mutagenesis. Cloned genes can be reintroduced into the C. elegans germ line by microinjection of DNA into the syncytial ovary of the hermaphrodite worm or into oocyte nuclei. The injected DNA usually forms extrachromosomal tandem arrays. Reintroduced genes are expressed and can suppress (rescue) a mutant phenotype. Selectable genetic markers are used to identify transformed worms.
The C. elegans genomic DNA and Expressed Sequence Tag databases contain sequences that show significant similarities to a large number of enzymes involved in both N-and O-glycan synthesis. C. elegans has three GlcNAcT I genes (gly-12, gly -13, gly-14) [98]. We have used UV irradiation in the presence of trimethylpsoralen as a mutagenic agent to obtain worms with null mutations in gly-12, gly-13 and gly-14 as well as a gly-14/gly-12 double null mutant [99, 100] . The gly-12, gly-14 and gly-14/gly-12 null mutants all had apparently normal phenotypes [99, 100] and a wild-type pattern of N-glycan composition, as revealed by MS (Figure 1 Table 1) . Assays of extracts of wild-type worms showed a very low GlcNAcT I activity with Man3-octyl and a relatively high activity with Man 5 -R ( Table 1) . Extracts of the gly-14/gly-12 double null mutant showed no detectable activity with Man3-octyl, but the same activity as wild-type worms when Man 5 -R was used as an acceptor substrate (Table 1) , leading to the conclusion that GLY-13 is the major GlcNAcT I enzyme in the wild-type worm. Consistent with this conclusion is the finding that most gly-13 null worms die at the L1 stage of development; however, a small percentage of these worms survive, but they have a starved appearance, frequent morphological abnormalities, egg-laying defects, and reproduce at a much reduced rate. The lethal mutation has been mapped to within approx. 8 kb on either side of the gly-13 gene, indicating a high probability that lethality is caused by the lack of gly-13 expression.
Although there is a great deal of variation between different plants, several plant species (almond, hazelnut, pistachio, potato, tomato, walnut) have been shown to accumulate over 30% of their N-glycans as the paucimannose Man 3 -R compound Man␣1, 6(Man␣1,3)(Xyl␤1,2) Man␤1,4GlcNAc␤1,4(Fuc␣1,3)GlcNAc-Asn-Xaa [101] . Since both the ␤1,2-xylosyltransferase and the core ␣1,3-fucosyltransferase require prior action of GlcNAcT I [102] , the formation of these paucimannose compounds indicates that a ␤-N-acetylglucosaminidase, which is presumably located in the Golgi apparatus, removes the GlcNAc␤1,2 residue from the N-glycan core while the nascent glycoprotein traverses the lumen of the endoplasmic reticulum-Golgi assembly line [103, 104] . Similarly, insects have been shown to accumulate the paucimannose Man␣1,6(Man␣1,3)Man␤1,4GlcNAc␤1,4(ϮFuc␣1,3)GlcNAc-Asn-Xaa glycans and to have a specific membrane-bound ␤-N-acetylglucosaminidase which presumably acts within the lumen of the assembly line during N-glycan biosynthesis [105, 106] .
We have obtained evidence for a similar mechanism in C. elegans. (Figure 1 ). There is also a small MS peak of Hex 3 HexNAc 3 ( Figure 1 ) that is presumed to be caused by the truncated hybrid structure Man␣1,6{GlcNAc␤1,2Man␣1,3}Man␤1,4GlcNAc␤1,4GlcNAc (Figure 2 ) and therefore to be indicative of prior GlcNAcT I action. The accumulation of paucimannose N-glycans in C. elegans suggests that worms have a ␤-N-acetylglucosaminidase similar to the enzyme in plants and insects (Hase; Figure 2 ). GLY-13 cannot act on the Man 3 -R compounds and, therefore, formation of these compounds is expected to be a metabolic 'dead end' in C. elegans. Indeed, the peaks for Man␣1,6(Man␣1,3)Man␤1,4GlcNAc␤1,4(ϮFuc)GlcNAcAsn-Xaa are relatively large (Figure 1 ). Since previous GlcNAcT I action is essential for the actions of both ␣3,6-mannosidase II and core FucT (Figure 2 ), these Man 3 -R compounds, either with or without a core Fuc, are believed to be 'footprints' of prior GlcNAcT I action. In an attempt to provide evidence for this hypothesis, we have carried out MS analyses on N-glycans isolated from a C. elegans strain with a null mutation in the gly-13 gene, which encodes the major GlcNAcT I enzyme in the wild-type worm. N-glycans from wild-type and gly-13 null worms were Figure 2 Conversion of oligomannose N-glycans to hybrid and paucimannose N-glycans in wild-type and gly-13 null mutants of C. elegans. This figure shows the conversion of oligomannose N-glycans (Man 9-5 GlcNAc 2 -Asn-Xaa) to hybrid and paucimannose N-glycans (M, mannose; Gn, GlcNAc; Hex, hexose; HexNAc, N-acetylhexosamine; R, GlcNAc␤1,4GlcNAc-Asn-Xaa). Man 9 GlcNAc 2 -Asn-Xaa is converted into Man 5 GlcNAc 2 -Asn-Xaa by the sequen-compared quantitatively by differential methylation with deuterated and non-deuterated iodomethane respectively (see legend to Figure 1 ). The samples were pooled and analysed by electrospray ionization-ion trap-MS (ESI-IT-MS). Eight N-glycan species were identified by their m/z values, and the ratio of the MS peak sizes (gly-13 null relative to wild-type worms) for each structure was calculated (Figure 2 ). tial action of ␣1,2-mannosidase(s). GlcNAcT I adds a GlcNAc in ␤1,2 linkage to the Man␣1,3-arm of Man 5 GlcNAc 2 -Asn-Xaa to form the hybrid N-glycan GlcNAc 1 Man 5 GlcNAc 2 -Asn-Xaa. C. elegans has three GlcNAcT I genes (gly-12, gly-13, gly-14) [98]. GLY-13 is the major GlcNAcT I enzyme in the wild-type worm (see text). The broken arrows for GLY-12 and GLY-14 indicate that these activities play minor roles in N-glycan synthesis in wild-type worms in vivo. Two Man residues are removed from the product of GlcNAcT I by the action of ␣3,6-mannosidase II (MII) to form the truncated hybrid N-glycan GlcNAc 1 Man 3 GlcNAc 2 -Asn-Xaa. Core fucosyltransferase (FucT) may add a Fuc to the Asn-linked GlcNAc, as indicated in the figure. Both ␣3,6-mannosidase II and FucT require the prior action of GlcNAcT I, and the resulting GlcNAc␤1,2Man␣1,3-moiety, for their actions. Wild-type C. elegans accumulates the paucimannose N-glycans Man␣1,6(Man␣1,3)Man␤1,4GlcNAc␤1,4(ϩ/ϪFuc) GlcNAc-Asn-Xaa (Figure 1) , probably due to the action of a specific ␤-N-acetylglucosaminidase (Hase; broken arrows indicate that the presence of this activity in C. elegans has not as yet been proven directly). GLY-13 cannot act on the Man 3 -R compounds (see text) and therefore, formation of these compounds is expected to be a metabolic 'dead end' in C. elegans. Since prior action of GlcNAcT I is essential for the actions of both ␣3,6-mannosidase II and core FucT, the paucimannose Man 3 -R compounds are 'footprints' of prior GlcNAcT I action. N-glycans from wild-type and gly-13 null mutant worms were methylated differentially with deuterated and non-deuterated iodomethane and analysed by ESI-IT-MS (see Figure 1) . The ratio of the MS peak sizes (gly-13 null relative to wild-type worms) for each structure is shown after the N-glycan composition. The data indicate that absence of GLY-13 (blocked arrow) results in significant increases in the amounts of Man 5-8 GlcNAc 2 -Asn-Xaa structures and significant decreases in Man␣1,6(GlcNAc␤1,2Man␣1,3) Man␤1,4GlcNAc␤1,4GlcNAc-Asn-Xaa and the paucimannose structure Man␣1,6(Man␣1,3)Man␤1,4GlcNAc␤1,4(ϮFuc)GlcNAc-Asn-Xaa. MS peaks for Hex [4] [5] (Figures  1 and 2 ) is presumably synthesized after the conversion of Hex 5 HexNAc 3 into Hex 4 HexNAc 3 by ␣3,6-mannosidase II followed by the action of ␤-N-acetylglucosaminidase. Hex 4 HexNAc 2 Fuc 1 can be formed as indicated in the figure. Several peaks, that are suggestive of N-glycans with more than one Fuc residue, have also been reported in C. elegans [110] . Evidence for the synthesis of significant amounts of truncated bi-, tri-and tetra-antennary complex N-glycans by C. elegans has been obtained (see text); these compounds are presumably formed by the action of GlcNAcT II at the arrows with the asterisk, followed by the actions of other branching GlcNAc-transferases. There are, however, detectable levels of Hex 3 HexNAc 3 , Hex 3 HexNAc 2 and Hex 3 HexNAc 2 Fuc 1 in the gly-13 null worm (Figure 2) . GLY-12 and/or GLY-14 may be at least partly responsible for the synthesis of N-glycans downstream of the GLY-13 block (Figure 2) . Interestingly, the gly-13 null mutation causes a smaller decrease in Hex 3 HexNAc 3 levels (ratio = 0.74) than in Hex 3 HexNAc 2 (ratio = 0.59) and Hex 3 HexNAc 2 Fuc 1 (ratio = 0.55) levels (Figure 2 ). Since there is no activity of GLY-13 on the paucimannose glycans (Hex 3 HexNAc 2 and Hex 3 HexNAc 2 Fuc 1 ) in both wild-type and gly-13 null worms, this shift towards Hex 3 HexNAc 3 in the gly-13 null worm suggests a compensatory up-regulation of GLY-12 and/or GLY-14 activity in the absence of GLY-13 and a partial reversal of ␤-N-acetylglucosaminidase action (Figure 2) . The presence of an '␣3,6-mannosidase III-like' enzyme, which can convert Man 5 GlcNAc 2 -Asn-Xaa into Man 3 GlcNAc 2 -Asn-Xaa without prior GlcNAcT I action [25] , can explain the formation of Man 3 GlcNAc 2 -Asn-Xaa but not of Man 3 GlcNAc 2 Fuc 1 -Asn-Xaa. The effect of lysosomal glycosidases during the worm extraction procedure is difficult to assess; however, extraction was carried out under conditions that minimize lysosomal hydrolase action.
The results described above have important implications. The usefulness of C. elegans in studying the role of complex N-glycans in development and other biological processes depends on the worm's ability to make reasonable amounts of these compounds. MS analysis of wild-type worms has shown little or no complex N-glycans and a relatively low level of GlcNAc 1 Man 3 GlcNAc 2 -Asn-Xaa, the product of ␣3,6-mannosidase II action ( Figure 1) ; however, our demonstration that the large MS peaks of Man␣1,6(Man␣1,3)Man␤1,4GlcNAc␤1,4(ϮFuc)GlcNAc-Asn-Xaa are indeed 'footprints' of previous GlcNAcT I action indicate that GlcNAcT I may play essential roles in C. elegans development. C. elegans has genes encoding enzymically active GlcNAcT II [111] , GlcNAcT V [112] and other glycosyltransferases [113, 114] required for complex N-glycan synthesis. Recent MS work by Haslam et al. (see Chapter 10 in this volume) has shown the presence in wild-type C. elegans of truncated bi-, tri-and tetra-antennary complex N-glycans in which C-6 of the terminal antennary GlcNAc residues is substituted with a phosphorylcholine group. Phosphorylcholine on N-glycans has been described previously [115] [116] [117] [118] and it interferes with MS identification of the glycan.
Functional post-translational proteomics approach to study the role of N-glycans in the development of C. elegans
This section outlines a general 'functional post-translational proteomics' approach to determine how N-glycans on individual glycoproteins function in the development of C. elegans. It is important to point out that this scheme is not meant to replace existing approaches, but rather to complement them. Projects such as the functions of Notch and dystroglycan (see above) will continue to be generated owing to scientific interest in specific glycoproteins. Mutant cell lines, mutant mice and other mutant organisms (C. elegans, Drosophila, etc.) will continue to provide clues in the study of specific glycoproteins. Our proteomics approach will, hopefully, locate other protein targets for the investigation of glycan function; however, since many proteins may not fulfil the requirements of the method, we have no illusions that our approach is capable of a comprehensive sweep. It should be pointed out that the biological 'read-out' of our screening is a change in the development of a metazoan organism rather than the 'read-outs' that are in common use in functional proteomics at present, i.e. a change in the pattern of gene expression or in the binding of proteins to other proteins.
Step 1: structural post-translational proteomics
We must first identify, on a proteomics scale, those C. elegans proteins that carry N-glycans. Worm extracts are subjected to chromatography on lectin columns, followed by two-dimensional isoelectric focusing-SDS/PAGE (2D-IEF-SDS/PAGE) ( Figure 3 ) [119] . Spots are cut from the gel, proteins are extracted and digested with trypsin, and peptides are purified and analysed by either matrix-assisted laser-desorption ionization-time-of-flight-MS or electrospray ionization-quadrupole-time-of-flight-MS (ESI-Q-TOF-MS). The instrument for the latter [120] is capable of peptide sequencing using nanoelectrospray tandem MS. We have shown (Figures 1 and 2 ) that N-glycans carrying the structure GlcNAc␤1,2Man␣1,3Man␤1-O-R and 'footprints' of GlcNAcT I action can be detected in extracts of C. elegans, indicating that GlcNAcT I is functional in the worm and that its products can be detected by MS. ESI-Q-TOF-MS analysis of a tryptic digest of one of the spots shown in Figure 3 As mentioned above, transgenic or 'knockout' glycosyltransferase mutations in mice and other animals can be used to identify some of the protein targets of the glycosyltransferase being studied. One method of achieving this is to compare 2D-IEF-SDS/PAGE patterns of wild-type and mutant animals. This strategy can be applied to C. elegans by comparing wild-type worms with gly-13 null worms.
A search of the Worm Proteome Database (WormPD; www.proteome. com/databases/index.html) with the search terms 'N-linked glycosylation', 'N-linked', 'N-glycosylation' and 'glycosylation' yielded 150 non-redundant 'hits'. Most of these are due either to the presence of the Asn-Xaa-Ser/Thr sequon or to the involvement of the protein in a glycosylation-related function (e.g. glycosyltransferases); in only a few cases (e.g. ost-1) was there direct evidence for N-glycan on the protein. Structural post-translational proteomics projects that target C. elegans glycans ('glycomics') by our group and others [110, 121, 122] will, hopefully, increase the number of experimentally established glycoproteins in the C. elegans database. Worm extracts were centrifuged to remove membranous organelles and the supernatants were subjected to chromatography on Concanavalin A columns followed by 2D-IEF-SDS/PAGE [119] . (A) Glycoproteins (0.4 mg) were first separated on a non-linear isoelectric focusing gradient of pH 3-10, followed by 12% SDS/PAGE. Gels were stained with silver. (B) Glycoproteins (1 mg) were first separated on a linear isoelectric focusing gradient of pH 4-7, followed by 12% SDS/PAGE. Gels were stained with Coomassie Brilliant Blue R-250. The circled spot was cut out of the gel, subjected to in-gel digestion with trypsin, and peptides were purified and analysed by ESI-Q-TOF-MS ( Figure 4A ).
Step 2: screening for known C. elegans mutants The next step in the procedure is to determine whether there are mutant worms corresponding to the glycoproteins identified in Step 1. If such mutants exist, they must have some sort of phenotype to be useful in our screening. When a potential glycoprotein target has been identified either by direct experimentation (Step 1, above) or by searching the WormPD, the entry for the relevant gene in the WormPD will contain information on mutant worm strains and their phenotypes. For example, the WormPD entry for the putative glycoprotein (CET-1, a member of the transforming growth factor-␤ superfamily) encoded by the gene dbl-1 indicates that there are six mutant alleles known for this gene. CET-1 has a single Asn-Ala-Thr sequon, but it is not yet known whether this site is occupied by an N-glycan [123] . Worms with homozygous null mutations in cet-1 have a readily detectable phenotype, i.e. shortened bodies and an abnormal male tail phenotype that resembles sma mutants (male sensory ray fusions), suggesting that cet-1, sma-2, sma-3 and sma-4 share a common pathway. CET-1 appears to affect body length in a dose-dependent manner. Heterozygotes for cet-1 dis- Figure 4A ) was analysed by ESI-Q-TOF-MS/MS. The amino acid sequence tag Glu-Leu-Gly-Leu-Gly, ions at m/z 470.34 and 939.58 at the respective ends of Glu-Leu-Gly-Leu-Gly, and the mass of the neutral parent (1153.73) were submitted to the Peptide Search algorithm and yielded the sequence Thr-Ile-Gly-Leu-Gly-Leu-Glu-Pro-Ile-Ile-Lys. This allowed identification of hypothetical protein T13F3.6 with a molecular mass of 21 742 Da, which is consistent with the molecular mass observed by 2D-IEF-SDS/PAGE in Figure 3 (B) (circled).
played body lengths ranging between those observed for the null mutant and those for the wild-type. Injection of a plasmid construct encoding the wild-type cet-1 genomic DNA was able to rescue the null mutant phenotype [123] . This observation is important for Step 3 of the screening.
Step 3: preparation of hypoglycosylating transgenic worms Genes can be introduced into the C. elegans germ line of mutant strains by microinjection of DNA into the syncytial ovary of the hermaphrodite worm [98] . The ability to rescue the mutant worm phenotype with a wild-type transgene is essential to the screening. If rescue is successful, transgenic worms will be prepared with genes in which the Asn-Xaa-Ser/Thr sequon(s) have been mutated so that N-glycosylation cannot occur. If a sequon-mutated gene is unable to correct the phenotype, either completely or partially, the stage is set for studying the role of N-glycans of a specific glycoprotein on a specific step in worm development.
Failure to rescue a phenotype may result if the absence of glycans prevents proper protein folding with subsequent destruction of the protein by the 'quality control' mechanism of the cell. Quality control problems will be detected by insertion of an epitope-tagged (e.g. Myc) version of the sequonmutated gene into the mutant worm followed by Western blot analysis on extracts of the resulting transgenic worm [98] .
Conclusions
It is likely that at least 50% of the genes in any metazoan genome encode N-glycosylated proteins [74] . While methods for structural analysis of protein glycosylation on a proteomics scale are being developed and applied, there have been few, if any, attempts to develop a corresponding functional post-translational proteomics approach. The approach suggested in this chapter does not provide a comprehensive screening method, as many proteins in the proteome will undoubtedly not fulfil the criteria required for the screen. The method is therefore designed to complement other approaches towards understanding glycan functions. The method requires a mutant organism with a genetic defect in the protein being studied and with a detectable phenotype. C. elegans has been chosen as an initial target organism to take advantage of the large number of known mutant strains in the database. Furthermore, scientists who study C. elegans have organized a Knockout Consortium (http://elegans.bcgsc.bc.ca/knockouts.html), which produces worms with null mutations on request and stocks a fairly large number of previously prepared null mutants. Other organisms such as D. melanogaster can also be studied by this approach.
Functional post-translational proteomics is inherently not a highthroughput method, but rather a general protein-by-protein approach to identify glycoproteins in the proteome that require their glycans for normal function. Our method uses normal development of the worm as a biological 'read-out' and should identify proteins essential for development that carry one or more asparagine-linked N-glycans necessary to this function. Although much of our previous work has focused on the role of hybrid and complex Nglycans in development, the proteomics approach targets all N-glycans. An analogous approach targeting only hybrid and complex N-glycans on individual proteins has not as yet been devised. When a glycoprotein has been positively identified by the screening, the specific biochemical and biological mechanisms of glycan function will require the kind of detailed study described above (see the section 'Function of specific glycans on specific glycoproteins').
The task of deciphering the mechanisms of action of glycosylation and other post-translational modifications is certainly daunting; however, the exciting recent work on proteins such as Notch and dystroglycan (described above) indicate that the rewards will undoubtedly be worth the effort. 
